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Diabetes mellitusAbstract Background: Diabetes mellitus (DM) is a metabolic disease that is associated with dis-
turbed carbohydrates, lipids and protein metabolism due to insulin deficiency and/or impaired insu-
lin action. Recently epigenetic mechanisms were shown to be involved in endocrine cell
differentiation and islets function. Procainamide which is a cardiac antiarrhythmic drug has been
recently classified as one of the epigenetic drugs targeting DNA methylation.
Aim: The present study was designed to evaluate the effect of procainamide as a demethylating epi-
genetic agent on streptozotocin-induced type 2 diabetes mellitus in rats.
Methods: Fifty adult male albino rats of weight ranging from 150 to 200 g were included in this
study. Rats were divided into five groups (each of 10 rats) as follows: group I: served as a normal
control group, group II: diabetic rats that received 1 ml gum acacia 2% orally, daily for 4 weeks,
group III: diabetic rats that received procainamide (20 mg/kg body weight)/day, orally for 4 weeks,
group IV: diabetic rats that received metformin (300 mg/kg/day), orally for 4 weeks, group V: dia-
betic rats that received both procainamide and metformin in the same previous doses for 4 weeks.
The following parameters were assessed in rats of all studied groups: fasting blood glucose level,
serum insulin level, serum tumor necrosis factor alpha (TNF-a) (as a proinflammatory cytokine
as well as an indirect biomarker of DNA methylation) and DNA methyltransferase enzyme
(DNMT) activity in pancreatic tissues (as a direct marker of DNA methylation).
Results: The present study revealed that combined administration of both procainamide and met-
formin produced a statistically significant reduction of fasting blood glucose levels as compared to
untreated diabetic rats as well as diabetic rats treated by either procainamide or metformin alone. InTNF-a,
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66 W.F. El-Hadidy et al.addition, procainamide administration either alone or in combination with metformin resulted in a
statistically significant rise of serum insulin levels. TNF-a levels were statistically elevated in dia-
betic untreated rats as well as those treated with metformin only while procainamide intake led
to its statistical decrease. Also, procainamide administration produced a statistically significant
reduction in the activity of DNA methyltransferase in pancreatic tissues reflecting its possible role
as a demethylating agent that increases insulin expression and release by pancreatic cells.
Conclusion: The present work could provide a proof of concept that procainamide could be used as
a possible therapeutic potential in type 2 diabetics as an epigenetic demethylating agent to increase
insulin levels and it is better to be used in combination with oral hypoglycemic agent e.g. metformin
to decrease insulin resistance.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Diabetes mellitus (DM) is a group of metabolic diseases char-
acterized by hyperglycemia resulting from defect in insulin
secretion, insulin action or both and it is associated with dis-
turbed carbohydrates, lipids and protein metabolism.1 DM
can be classified according to the treatment required to control
it into insulin dependent (type 1) and non-insulin dependent
(type 2) diabetes or it may be classified according to the age
at which the disease develops into juvenile or maturity onset
diabetes. Pathogenesis of DM represents a complex of interac-
tion between metabolic, genetic and environmental factors as
well as inflammatory mediators.2
Evidence are emerging that several diseases and behavioral
pathologies result from defects in gene functions. The best
studied example is cancer but other diseases such as autoim-
mune diseases, asthma, type 2 diabetes and metabolic disor-
ders display aberrant gene expression. Gene function may be
altered by either change in the sequence of DNA or change
in epigenetic programming.3
Epigenetic information is defined as heritable information
other than the DNA sequence that is critical to the proper
functioning of the gene .These epigenetic alterations are
potentially reversible and DNA methylation represents the
most characterized epigenetic modification. It is represented
by methylation of cytosine residues within the context of
the cytosine–phosphate–guanine (CpG) dinucleotide which
is catalyzed by enzymes belonging to the DNA methyltrans-
ferases family (DNMTs). Although the density of CpG sites
in the genome is very low, there are clusters of CpG sites,
known as ‘CpG islands’, which are generally kept unmethy-
lated. The CpG islands remain free of methylation and are
associated with transcriptionally active genes, predominantly
so-called ‘housekeeping’ genes. When a CpG island in the
promoter region of a gene is methylated, expression of the
gene is repressed.4
With epigenetic drugs, it is possible to reverse aberrant gene
expression profiles associated with different disease states and
several epigenetic drugs targeting DNA methylation has been
tested in clinical trials. Understanding the epigenetic machin-
ery and the differentiation roles of its components in specific
disease states is essential for developing targeted epigenetic
therapy.5
Recently, epigenetic mechanisms were shown to be involved
in pancreatic endocrine cell differentiation and islet function.
In depth understanding of epigenetic landscape can help toimprove protocols to enhance pancreatic beta cells prolifera-
tion and lead to the discovery of novel therapeutic agents.6
Inhibitors of DNA methyltransferases may be either nucle-
oside analogs such as 5-aza-20deoxycytidine, decetabine and
zebularine or non-nucleoside such as procainamide and
hydralazine. Procainamide is a cardiac antiarrhythmic drug
that has been approved for treatment of life threatening
ventricular arrhythmias. Recently it has been classified as
one of DNA demethylating epigenetic agents with growth
inhibitory effects in human cancer cells.7 Therefore, the present
study aimed to assess the possible protective effect of procain-
amide as a demethylating epigenetic agent on experimentally
induced type 2 DM in rats.
2. Material and methods
This study was carried out on fifty adult male albino rats of
body weight ranging from 150 to 200 g. They were housed un-
der the same environmental conditions of light and tempera-
ture, fed standard diet and had free access to water. The
study protocol was approved by ethics committee of Faculty
of Medicine, Alexandria University.
The animals were divided into five groups (each of 10 rats)
as follows:-
Group I (normal control group): This group received 1 ml of
0.1 M sodium citrate buffer (pH 4.5) intraperitoneally (i.p.).
The remaining 40 rats were subjected to induction of type 2
DM by a single i.p. injection of 40 mg/kg body weight strepto-
zotocin (STZ) (Sigma Chemical Co., Switzerland) after being
dissolved in 0.1 M sodium citrate buffer (pH 4.5).8 One week
after STZ injection, rats were assessed for hyperglycemia.9
When DM was developed, rats were randomly assigned
into the following groups:
Group II (diabetic untreated group): This group included
rats with induced DM that received 1 ml of 2% gum acacia/
day (Arabic Laboratory Equipment Co.) orally for 4 weeks.
Group III (procainamide-treated diabetic group): This group
included diabetic rats that were given procainamide orally for
4 weeks in a daily dose of 20 mg/kg body weight.10
Group IV (metformin-treated diabetic group): This group
involved diabetic rats that received metformin (as oral
anti-diabetic drug of biguanide class that decreases insulin
resistance) in a daily dose of 300 mg/kg body weight orally
for 4 weeks.11
Group V (procainamide- and metformin-treated diabetic
group): Rats of this group were given both procainamide and
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durations.10,11 The calculated doses of either procainamide,
metformin or both were dissolved in 1 ml of 2% gum acacia
and were given via an oral gavage syringe.
At the end of the experiment, rats of all groups were fasted
for 8–12 h with free access to water. Rats were then anesthe-
tized by ether and blood samples were withdrawn from medial
retro-orbital venous plexus using capillary hematocrit tube.12
Blood samples were left to coagulate at 37 C and then were
centrifuged for 15 min at 3000 rpm. Sera were separated and
stored at 20 C until being used. After taking blood samples,
rats were sacrificed and pancreases were rapidly excised, imme-
diately washed with ice-cold saline, blotted on dry filter papers,
weighed and then homogenized using a kit to separate nuclear
proteins (Epiquik Nuclear Extraction kit II; Epigentek, NY,
USA) as follows:133. Cell pellet preparation
1. The pancreatic tissue was cut into small pieces, then placed
in a clean homogenizer.
2. 10· Pre-extraction buffer (NP1) was diluted with distilled
water at a 1:10 ratio, and 5 ml of diluted NP1 (1·) contain-
ing 5 ll of dithiothreitol (DTT) were added per gram of tis-
sue and tissue pieces were homogenized (50–60 strokes),
then incubated on ice for 15 min.
3. Centrifugation was done for 10 min at 12,000 rpm at 4 C
and the supernatant was removed and discarded.4. Nuclear extract preparation
1. DTT solution and protease inhibitor cocktail (PIC) were
added to extraction buffer (NP2) at a 1:1000 ratio, followed
by adding extraction Pre-Cleaner (NP3) to NP2 at 1:10
ratio. Two volumes of NP2 were added to nuclear pellet
(about 10 ll NP2 per 2 mg tissues). The extract was incu-
bated on ice for 15 min. with vortex (5 sec.) every 3 min.
The extract was further sonicated for 3 · 10 s to increase
nuclear protein extraction.
2. The suspension was centrifuged for 10 min. at 14,000 rpm
at 4 C and the supernatant was transferd into a new micro-
centrifuge vial.
3. The Extraction Cleaner (NP4) was added to the superna-
tant at a 1:100 ratio (ex: 10 ll of NP4 to 990 ll of the super-
natant) and incubated for 15–20 min at room temperature.
4. The suspension was centrifuged for 1 min at 14,000 rpm at
4 C and the supernatant was transferd into a new micro-
centrifuge vial.
5. The protein concentration of the nuclear extract was
measured.
6. The supernatant was kept at 80 C until further use for
determination of DNA methyltransferase (DNMT)
activity.
The following parameters were measured in all the studied
groups:
1- Serum levels of fasting blood glucose; by using glucose
oxidase method.142- Serum insulin levels using a solid phase enzyme ampli-
fied sensitivity immunoassay.15
3- Serum levels of tumor necrosis factor-alpha (TNF-alpha)
(as a proinflammatory cytokine as well as an indirect
biomarker of DNA methylation) using quantitative
sandwich enzyme immunoassay technique.16
4- DNA methyltransferase (DNMT) activity (as a direct
marker of DNA methylation) in pancreatic tissues was
measured colorimetrically (Epiquick DNA methyltrans-
ferase activity/inhibition assay kit) in accordance with
the manufacturer’s instructions.13
5. Statistical analysis
Data were expressed as means with their corresponding stan-
dard deviation (SD). A one way analysis of variance (ANOVA
or F test) using the statistical package of social sciences (SPSS)
was used to compare more than two means. Association be-
tween different parameters was determined using Pearson’s
correlation coefficient (r). Statistical significance was set at
P values less than 0.05.
6. Results
6.1. Serum levels of both fasting blood glucose and insulin in the
studied groups as shown in Table 1 and Figs. 1 and 2
The present study revealed that fasting blood sugar levels
showed a statistically significant elevation in groups II (dia-
betic untreated group), III (procainamide-treated diabetic
group) and IV (metformin treated diabetic group) as compared
to normal healthy controls of group I as well as to rats of com-
bined procainamide and metformin treated of group V.
(F= 75.79 and P = 0.0001).
On the other hand, regarding serum insulin levels, the cur-
rent study showed that there was a statistically significant
reduction of serum insulin levels in group II and group IV as
compared to groups I, III and V but there was no statistically
significant difference between the insulin levels in rats of
groups III and V. (F= 5.931 and P = 0.001).
6.2. Serum levels of tumor necrosis factor-alpha (TNF-alpha)
and pancreatic tissue activity of DNA methyltransferase
(DNMT) in the studied groups as shown in Table 2 and Figs. 3
and 4
The present work revealed that oral administration of procain-
amide either alone in diabetic rats of group III or in combina-
tion with metformin in diabetic rats of group V for 4 weeks
had resulted in a statistically significant decrease in the serum
levels of TNF-alpha as compared to those rats of groups I , II
and IV. There was a statistically significant increase in serum
levels of TNF-alpha in groups II and IV as compared to nor-
mal healthy controls of group I (F= 5.12 and P = 0.002).
Considering pancreatic tissue activity of DNA methyltrans-
ferase (DNMT) in the studied groups, the current study
showed a statistically significant reduction in the activity of
DNMT of pancreatic tissues of rats treated with procainamide
Figure 1 Serum levels of fasting blood glucose (mg/dl) in the
studied groups.
Figure 3 Serum levels of TNF-alpha (pg/ml) in the studied
groups.
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groups (groups I, II and IV) (F= 76.4 and P = 0.0001).
6.3. Correlation between serum levels of fasting blood glucose
and insulin as well as tumor necrosis factor-alpha (TNF-alpha)
and pancreatic tissue activity of DNA methyltransferase
(DNMT) in the studied groups as shown in Table 3
The present study revealed that there was a statistically signif-
icant negative correlation between serum levels of FBS and
serum insulin levels (P = 0.015). On the other hand, there
was a statistically significant positive correlation between ser-
um levels of FBS and serum levels of TNF-alpha as well as be-
tween pancreatic tissue activity of DNMT and serum levels of
TNF-alpha (P = .020 and 0.0351, respectively).
N.B. the letters a, b, c, d in Tables 1 and 2 are called Dun-
can letters & are used to detect the least significant difference
(LSD) in ANOVA study.
7. Discussion
Type 2 diabetes mellitus (DM) involves insulin resistance and
relative insulin deficiency rather than absolute insulinFigure 2 Serum insulin levels (l IU/ml) in the studied groups.deficiency. Insulin resistance has been proposed to be the ini-
tial step in the cascade towards diabetes. Its actual mechanism
is not completely understood that may be related to several
factors as leptin, TNF-alpha and other substances. Moreover,
genetic polymorphism may play an important role in its
pathogenesis.17
The mechanism of b-cell failure in type 2 diabetes is un-
known, in addition to a genetic predisposition, many studies
demonstrated higher rates of apoptosis and decreased mass
of pancreatic b-cells.18,19
Changes in the normal program of gene expression are the
basis for several human diseases. Gene function may be altered
by either a change in the sequence of the DNA or a change in
the epigenetic programming of a gene in the absence of se-
quence change. So, with epigenetic drugs, it is possible to re-
verse aberrant gene expression profile associated with
different disease states.20
The goal of the present study was to clarify the possibility
of using an epigenetic modifying agent as procainamide in
cases of experimentally induced type 2 DM as a possible ther-
apeutic potential either alone or in combination with oral
hypoglycemic agent as metformin.
There was a statistically significant elevation of fasting
blood glucose levels of diabetic untreated rats & those treatedFigure 4 Pancreatic tissue activity of DNA methyltransferase
(IU/gm tissue) in the studied groups.











diabetic rats (n = 10)
Group V (procainamide
and metformin treated
diabetic rats) (n= 10)
Fasting blood glucose level (mg/dl)
Range 70–118 190–325 165–213 110–157 88–129
Mean ± SD 95.1 ± 16.26a 250.1 ± 45.59b 192.3 ± 15.58c 135.6 ± 14.21d 106.8 ± 13.15a
F 75.79
P 0.0001*
Serum insulin level (l IU/dl)
Range 7.8–16.1 4.3–11.1 6.1–12.1 5.1–10.3 7.2–12.9
Mean ± SD 12.02 ± 2.80a 8.38 ± 2.25b 9.95 ± 1.74ab 8.25 ± 1.73b 10.88 ± 1.80ab
F 5.913
P 0.001*
Different letters indicate statistically significant difference.
Statistical significance was set at P values less than 0.05.
The meaning of each group was written in the upper row of each table.














diabetic rats (n= 10)
Group V
(procainamide and
metformin treated diabetic rats)
(n= 10)
Serum levels of TNF-alpha (pg/ml)
Range 10.8–20.1 19.7–25.3 14.2–20.9 12.9–25.5 11.2–21.5
Mean ± SD 15.56 ± 3.63a 21.91 ± 1.97b 18.35 ± 2.15c 20.4 ± 4.51b 17.84 ± 4.04c
F 5.12
P 0.002*
Pancreatic tissue activity of DNA methyltransferase (IU/gm tissue)
Range 0.7–0.93 0.72–0.99 0.33–0.67 0.7–0.89 0.25–0.49
Mean ± SD 0.84 ± 0.08a 0.834 ± 0.08a 0.474 ± 0.11b 0.793 ± 0.06a 0.336 ± 0.07b
F 76.4
P 0.0001*
Different letters indicate statistically significant difference.
Statistical significance was set at P values less than 0.05.
The meaning of each group was written in the upper row of each table.
Table 3 Correlation between serum levels of fasting blood glucose and insulin as well as tumor necrosis factor-alpha (TNF-alpha) and
pancreatic tissue activity of DNA methyltransferase (DNMT) in the studied groups.
Fasting blood
glucose
Serum insulin Serum level of
TNF-alpha
Serum insulin Pearson Correlation (r) .343*
P .015




Pearson Correlation (r) .146 .094 .235*
P .311 .517 .0351
* Correlation is significant at the 0.05 level (2 - tailed).
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normal or those treated by both procainamide and metformin.
Serum insulin levels were significantly elevated in rats treated
with procainamide either alone or in combination with metfor-
min, when compared to those treated only with metformin.These results could reflect the possible role of procainamide
as an agent that increased expression and release of insulin
from pancreatic b-cells due to its epigenetic modifying effect
in diabetes treatment. These findings are consistent with results
of Bramswig et al.21 study that reported that epigenetic
70 W.F. El-Hadidy et al.mechanisms were shown to be involved in endocrine cell differ-
entiation and islet function and could enhance b-cell prolifera-
tion and may lead to the discovery of novel therapeutic target.
Regarding serum levels of TNF-alpha, results of the current
work showed a significant elevation in diabetic untreated rats
and those treated by metformin alone but procainamide treat-
ment resulted in a significant reduction of TNF-alpha levels.
These findings indicate the probable inflammatory role of
TNF-alpha as a mediator in the pathogenesis of DM.
Our results were in accordance to the finding reported by
Hu et al.22 Recent research done by Mirza et al 23 reported that
diabetes as whole was strongly associated with elevated levels
of IL-6, leptin, C-reactive protein and TNF-alpha and there
was an association between low-grade inflammation and qual-
ity of glucose control.
Also, the same finding was reported in a study done by Ja-
tla et al.24who stated that TNF-alpha inhibits insulin transduc-
tion and has an effect on glucose metabolism. Moreover, it was
found that TNF-a could be a contributing factor to diabetic
complications such as atherosclerosis25 and dyslipidemia.26
Similar to our findings, Tousoulis et al 27 reported that
TNF-a serum levels remained unchanged in diabetic patients
treated by metformin alone but, these levels were reduced in
those treated by a combination of metformin and atorvastatin.
Also, it was found that metformin alone did not improve the
plasma concentrations of inflammatory markers and adipo-
kines in patients with type 2 DM.28 But, in contrary to our
findings, Derosa et al 29 reported that metformin led to a sig-
nificant reduction in inflammatory state parameters in poorly
controlled type 2 diabetic patients.
However, no studies were found that spoke on the effect of
PA on TNF-alpha level or expression.
Considering pancreatic tissue activity of DNA methyltrans-
ferase (DNMT), the results of the present study revealed that it
was higher in both diabetic untreated rats and metformin
alone treated ones, but procainamide either alone or in combi-
nation with metformin reduced its pancreatic activity. These
results could suggest that DNA methylation during insulin
synthesis by b-cells may be implicated in the pathogenesis of
decreased insulin levels and consequently diabetes mellitus,
whereas procainamide could emerge as a potential demethylat-
ing agent for clinical translation.
Many lines of evidence indicate that procainamide inhibits
DNMT by reducing its affinity with its two substrates which
are hemimethylated DNA and adenosyl methionine.30
Moreover, in a study performed on adult rats with diabetes,
it was found that there was an interaction between diabetes
and status of gene methylation. Thus a demethylating agent
could down regulate the expression of DNMT and hence,
may guide the development and evaluation of new treatment
modalities for patients with diabetes.31
Epigenetics provide a mechanism which may explain the
etiology of type 2 diabetes, obesity and other human diseases
such as cancer.32 DNA methylation is an epigenetic modifica-
tion that plays a key role in various biological processes and it
is believed to be modulated by environmental and nutritional
factors and essentially functioning as a molecular switch to
turn genes on or off.33
In the current work, there was a significant positive correla-
tion between serum levels of TNF-alpha and pancreatic tissue
levels of DNMT. This finding was in accordance to the study
performed in 200934 and reported that baseline TNF-alphacirculating levels were positively correlated with total methyla-
tion and could be a good marker for DNA methylation.
Finally, to sum up, our data provide a proof of concept that
procainamide could be pharmacologically exploited to develop
a novel DNA methylation inhibitor that may be used in type 2
diabetes to increase insulin expression and release. It could
also be used in combination with other anti-diabetic drugs that
decrease insulin resistance as metformin. The exact roles of
procainamide as an epigenetic demethylating agent in different
body systems deserve further investigations in the future
researches.Conflict of interest
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